Investor Overview

Corporate Profile

Oncobiologics is a clinical stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics. Our current focus is on technically challenging and commercially attractive monoclonal antibodies (mAbs), in the disease areas of immunology and oncology. Our strategy is to leverage our BioSymphony™ Platform to cost-effectively develop these biosimilars on an accelerated timeline, which is fundamental to our success and we believe positions us to be a leading biosimilar company.

Latest News

July 06, 2016

Oncobiologics, Inc. to Present at the 2016 Cantor Fitzgerald 2nd Annual Healthcare Conferencemore >

June 16, 2016

Oncobiologics Announces First CTA Approvals for Global Phase 3 Clinical Program for ONS-3010 (Humira® biosimilar)more >

June 10, 2016

Oncobiologics Announces Separation of Units; Trading of Common Stock and Warrantsmore >

Upcoming Events

There are currently no events scheduled.